Physician profile
Stephen Denagy
NPI 1336273085
$5,774.36
in general payments reported to CMS, 2019-2025
30 companies · $618 in 2025
The $618 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $996 · 2021: $755 · 2022: $666 · 2023: $796 · 2024: $582 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,880 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,880.30 |
| Education | $115.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $896.77 | 2019-2021 | |
| Abbvie INC. | $867.74 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $601.12 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $526.14 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $464.41 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $340.67 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $274.41 | 2019-2025 | Invega Sustenna |
| Axsome Therapeutics, INC. | $184.46 | 2023-2025 | Auvelity |
| Indivior INC. | $177.56 | 2019-2025 | Sublocade, Perseris |
| Alkermes, INC. | $168.80 | 2019-2023 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $165.46 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $132.74 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $127.14 | 2021-2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $105.06 | 2019-2022 | |
| Neuronetics, INC. | $95.48 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $83.88 | 2019-2022 | |
| Corium, LLC | $76.65 | 2023-2025 | Azstarys |
| Livanova USA, INC. | $68.11 | 2019 | |
| Avanir Pharmaceuticals, INC. | $63.40 | 2019 | |
| Lundbeck LLC | $60.21 | 2021-2025 | Rexulti |
| Eisai INC. | $48.72 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $48.49 | 2019 | |
| Tris Pharma INC | $48.38 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $36.06 | 2024-2025 | Cobenfy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.68 | 2019 | |
| Nestle Healthcare Nutrition INC. | $21.86 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.22 | 2020 | |
| Novo Nordisk INC | $15.86 | 2023 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $14.95 | 2025 | General - Pain Management |
| Strongbridge US INC. | $11.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Denagy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.